New pancreatic cancer treatments have not been approved in many years, but the first half of 2026 has seen some significant treatment advances. In this episode, host Alisyn Camerota talks with Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical Officer, and Dr. Allyson Ocean, director of the pancreatic cancer research program at Weill Cornell Medicine and co-founder of Let's Win Pancreatic Cancer, about what's changing and what it means for patients.

Dr. Berkenblit and Dr. Ocean discuss the phase 3 results for daraxonrasib, a RAS-targeted therapy now available to some patients through an FDA expanded access program. They also cover the broader pipeline of RAS inhibitors and degraders in development, progress on personalized and off-the-shelf pancreatic cancer vaccines, and tumor-treating fields (TTF)—brand-name Optune Pax—a newly approved device-based therapy for locally advanced disease. Dr. Berkenblit and Dr. Ocean also focus on what these developments mean for patients navigating treatment decisions today, and why clinical trial participation remains central to progress in the field.

Thank you to our sponsor, Revolution Medicines.

Learn more at letswinpc.org and pancan.org.

Resources:

PanCAN Patient Services

Let’s Win Doctor Finder

PanCAN Clinical Trial Finder

Let’s Win Clinical Trial Finder

Accessing Daraxonrasib: A Quick Primer

PancChat is produced in collaboration with Let's Win Pancreatic Cancer and PanCAN.